TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03724032

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tDCS*
Description: Non-invasive brain stimulation (sham protocol)
Study: NCT00783237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone
Description: Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray, single dose of 2 sprays per nostril
Study: NCT02656537

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnSite™ HD Grid Catheter mapping system
Study: NCT04219007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vosoritide
Description: After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.
Study: NCT00072566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO
Study: NCT03396692

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine patient-controlled analgesia (PCA)
Description: Group 1 control:~* Morphine titration at 0.1 mg/kg~* Establishment of PCA morphine:~* concentration 1mg/ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day. Premedication of the patient with Ketamine 0.15 mg/kg and Propofol 0.5 mg /kg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Block of the posterior exo-thoracic fascia with Ropivacaine
Description: Group 2 PEF block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a block of the posterior exo-thoracic fascia (PEF block) at the median level of ribs fractures with ropivacaine 5mg / mL, 3 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of ropivacaine bolus 2mg / ml at 0.1ml/kg every 4 hours. Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Block of paravertebral space with Ropivacaine
Description: Group 3 paravertebral block:~* Establishment of PCA morphine:~* concentration 1mg / ml~* 1ml bolus~* refractory period of 7 minutes~* no maximum dose per day.~* Realization of a paravertebral block (BPV) at the median level of ribs fractures ropivacaine 5mg / mL, (0.3ml / kg) 1.5 mg / kg under echography guidance. ALR needle (type neurostimulation) with a length of 100 mm is used. When the injection is performed an analgesia catheter is deposited in the space created by local anesthetics. Realization of bolus of ropivacaine 2mg / ml at 0.1ml / kg every 4 hours.~Possibility of an additional bolus of 0.1ml / kg every hour if insufficient analgesia.~In the case of failure of initial management with significant pain despite the iterative boli, epidural analgesia is used in recourse.
Study: NCT01899027

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
Study: NCT02874430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Given orally
Study: NCT00001304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Synthetic Human Parathyroid Hormone 1-34
Description: twice daily subcutaneous injections
Study: NCT00072566

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02937675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tomivosertib (eFT-508)
Description: eFT508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tomivosertib (eFT-508)
Description: eFT508
Study: NCT02545556

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HepaSphere combined with cryosurgery
Description: liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
Study: NCT01904734

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
Study: NCT02938052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PP-based health behavior intervention
Description: The positive psychology exercises include 3 modules: Gratitude-based activities, Strength-based activities, and Meaning-based activities. The goal setting exercises include 3 modules: Physical activity, Heart-healthy diet, and Medication adherence.
Study: NCT02545556

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: HepaSphere combined with cryosurgery
Description: liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
Study: NCT03348150

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery + Gastrecomy
Description: Complete cytoreduction followed by a (sub)total gastric resection with D2 lymphadenectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
Description: HIPEC: perfusion with oxaliplatin (460mg/m2 ) (42 °C) followed by docetaxel (50mg/m2 ) (37°C)
Study: NCT01490749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: Patients will receive two cycles of XELOX.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given on a 3 weeks on and 1 week off schedule.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
Study: NCT00001304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitriol & Calcium
Description: Twice daily oral calcitriol with 1000 mg Calcium carbonate supplementation
Study: NCT03284086

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: upper-body double-poling
Description: An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: upper-body double-poling
Description: An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.
Study: NCT04427371

Intervention type: OTHER
Intervention: the levels of pyroptosis
Description: Blood samples were taken to detect plasma lncRNA NBR2 levels and GSDMD protein level.
Study: NCT03284086

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: arm crank ergometry
Description: An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: arm crank ergometry
Description: An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.
Study: NCT04523324

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flublok™ Quadrivalent by Sanofi, Inc.
Description: 0.5 mL intramuscular dose of Flublok

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VaxigripTetra™ by Sanofi, Inc.
Description: 0.5 mL intramuscular dose of Vaxigrip
Study: NCT04394338

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-gripping mesh placement with plastic sheath in laparoscopic inguinal hernia
Description: to apply these to the mesh graft placement process. In the first step, plastic sheaths self-gripping mesh placement with plastic sheathwere prepared configuration with the standard 9cmx15cm self-gripping mesh. Then the meshes were folded and unfolded over or under the plastic sheaths.
Study: NCT03245034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture Therapy
Description: Acupuncture treatment will be the NADA protocol, a well-known and commonly used protocol that has previously been studied for stress relief in health care workers.In this protocol, 5, ½ needles are inserted in each auricle and retained while the group relaxes for 20 minutes. It will be conducted by two acupuncturists credentialed at NYU Lutheran (TK and AG).
Study: NCT01582919

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuroimaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuroimaging
Study: NCT01272921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Varying doses to determine the duration of analgesia
Study: NCT00192569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alfa 2a
Description: PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (HIV conifected patients only)
Description: * genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg)~* Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
Study: NCT05334966

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Hyperoxygenation
Description: Oxygen is given to mothers at 8L through a non-rebreather mask.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal Hyperoxygenation
Description: Oxygen is given to mothers at 8L through a non-rebreather mask.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maternal Hyperoxygenation
Description: Oxygen is given to mothers at 8L through a non-rebreather mask.
Study: NCT01760629

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecotherm-HELIX
Description: Whole body cooling using Tecotherm-HELIX
Study: NCT01012193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol 100mg bid or clopidogrel 150-mg daily
Description: Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cilostazol 100mg bid or clopidogrel 150-mg daily
Description: Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
Study: NCT04771052

Intervention type: OTHER
Intervention: COVID Rehabilitation Program for the Elderly (CORE)
Description: In the intervention unit, two teams (core team: physiotherapists and service healthcare workers; specialized team: occupational therapist, registered dietician, social worker) are dedicated to the patients hospitalized in COVID-19 unit. To prevent malnutrition, caused by disease-associated inflammation, the Nutrition as Medicine program (prescribed small doses (30 or 60 mL; 2 kcal/mL) of oral nutrition supplement dispensed with medication pass, 1 to 4 times a day), has been systematically implemented (collective prescription). To improve muscle strength, balance and tissue oxygenation and concomitantly reduce immobilization and risk of falls, each patient has a private pedal exerciser, resistance elastic bands and free weights to perform a progressive, monitored and individualized rehabilitation program thrice a day.
Study: NCT00494871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Participants orally administered rivaroxaban 15 mg OD (CrCL \[creatinine clearance\] \>= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Participants orally administered a warfarin potassium tablet (INR \[international normalized ratio\] target was 1.6-2.6 for patients \>70 years and 2.0-3.0 for patients \<70 years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban placebo
Description: Participants orally administered a rivaroxaban placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin placebo
Description: Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
Study: NCT01829802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir boosted Atazanavir
Description: Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir boosted Atazanavir
Description: Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/FTC (or 3TC)
Description: Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
Study: NCT01760993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489
Description: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
Study: NCT02855684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine (U300)
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: Pharmaceutical form: solution~Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Non-insulin antihyperglycemic drugs
Description: Pharmaceutical form: capsule/tablet~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-insulin antihyperglycemic drugs
Description: Pharmaceutical form: capsule/tablet~Route of administration: oral
Study: NCT01907984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Study: NCT00734344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir 400 mg. BID
Study: NCT04333758

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jintronix Virtual Reality Telerehabilitation System
Description: System consists of an internet-based rehabilitation software linked to a Microsoft Kinect camera for motion detection.~Study team therapist prescribed a list of guided exercises and therapeutic activities (games) for training of whole body, lower and upper extremities. These can be done in sitting or standing, depending on individual participant's capacity.~Telemonitoring is done by study team therapist during each of the training day (Mondays-Fridays) of the home-based training phase. Training performance results are reviewed and training games are adjusted or changed to optimise home training.
Study: NCT00723450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamictal
Description: Flexible Dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lamictal
Description: Flexible Dosing
Study: NCT02968472

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: prophylactic 4SCAR19 cells
Description: Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
Study: NCT01147341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cimzia
Description: prefilled 200mg Cimzia syringe SC q 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: prefilled saline syringe
Study: NCT04000269

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soterix MxN Neuromodulation device
Description: Up to 2 mA stimulation to primary motor cortex for 10 sessions at 20min per session
Study: NCT03060837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Parameters
Description: Stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Movement of kidney
Description: Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Movement of kidney
Description: Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single lung ventilation
Description: Patients in this group will intubated with an endotracheal tube and then a bronchial blocker will be placed with the help of a fiberoptic bronchoscope or will be intubated with a double lumen endobronchial tube. One lung ventilation will be applied

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard ventilation
Description: Patients in this group will be intubated with standart single lumen endotracheal tubes and standart two lung ventilation will be applied.
Study: NCT01527565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 70
Description: A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
Study: NCT01937065

Intervention type: OTHER
Intervention: No treatment
Study: NCT00845702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine (Dotarem)
Description: Each subject will receive one injection of Dotarem 0.2 ml/kg

Intervention type: OTHER
Group type: OTHER
Intervention: Time of Flight Magnetic Resonance Angiography
Description: Each subject will undergo a TOF MRA
Study: NCT04000269

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Uses slight stimulation initially then turns of and provides no stimulation after a few seconds.
Study: NCT01272921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Varying doses to determine the duration of analgesia
Study: NCT01983514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8IU intranasal oxytocin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 IU intravenous oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02280720

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting using Optimax™

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting using PROMUS Element™ Plus
Study: NCT02623452

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)
Study: NCT02190448

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: study herbal tea
Description: 3-5 cups, 8oz tea daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: herbal placebo tea
Description: 3-5 cups, 8oz each daily for 4 weeks
Study: NCT03352375

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orotracheally intubation
Description: Interventions used for airway safety and ventilation during surgical procedures
Study: NCT04815863

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of somatic symptom disorder with SSS-CN
Description: SSS-CN questionnaire is used to assess the presence and severity of the somatic symptoms

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of somatic symptom disorder with SSS-CN
Description: SSS-CN questionnaire is used to assess the presence and severity of the somatic symptoms

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of depressive symptoms disorder with PHQ-9
Description: PHQ-9 questionnaire is used to assess the presence and severity of the depressive symptoms

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of depressive symptoms disorder with PHQ-9
Description: PHQ-9 questionnaire is used to assess the presence and severity of the depressive symptoms

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of anxiety disorder with GAD-7
Description: GAD-7 questionnaire is used to assess the presence and severity of the anxiety disorder

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of anxiety disorder with GAD-7
Description: GAD-7 questionnaire is used to assess the presence and severity of the anxiety disorder
Study: NCT00108381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tailored cognitive behavior therapy
Description: tailored psychological treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard care
Description: standard psychological treatment